Annual Report Reveals Deepening Losses, Major Goodwill Impairment, and Significant Tax Valuation Allowance

summarizeSummary

Cross Country Healthcare reported a significantly increased net loss of $94.9 million for 2025, a 21.6% revenue decline, and recorded substantial goodwill impairment and a deferred tax asset valuation allowance, confirming and detailing prior negative disclosures.

check_boxKey Events

• Net Loss Surges to $94.9 Million in 2025

  The company reported a net loss attributable to common stockholders of $94.9 million for the year ended December 31, 2025, a significant increase from the $14.6 million net loss in 2024. This finalizes the terms of the offering initiated on 2026-03-04.

• Revenue Declines 21.6% Year-over-Year

  Consolidated revenue decreased by 21.6% to $1.1 billion for 2025, primarily due to volume declines in the Nurse and Allied Staffing and Physician Staffing segments.

• Records $77.9 Million Goodwill Impairment

  A non-cash goodwill impairment charge of $77.9 million was recorded in the fourth quarter of 2025, primarily triggered by a decline in the company's equity market capitalization following the termination of the Aya Merger Agreement.

• Establishes $29.5 Million Deferred Tax Asset Valuation Allowance

  An additional valuation allowance of $29.5 million was recorded in Q4 2025 on deferred tax assets, indicating management's uncertainty about realizing these tax benefits due to cumulative losses.

auto_awesomeAnalysis

Cross Country Healthcare's annual report for fiscal year 2025 confirms and details a substantial deterioration in financial performance, building on the preliminary negative news from the recent 8-K filing. The company reported a significant net loss of $94.9 million, a sharp increase from the prior year, alongside a 21.6% revenue decline. A major non-cash goodwill impairment charge of $77.9 million and a $29.5 million valuation allowance on deferred tax assets highlight severe profitability challenges and uncertainty about future earnings. While the company received a $20.0 million termination fee from a failed merger agreement and continues a share repurchase program, these positive aspects are heavily outweighed by the overall financial and operational headwinds. Investors should be concerned about the company's ability to reverse these trends and achieve sustainable profitability.